Lan N C, Baxter J D
J Clin Endocrinol Metab. 1982 Sep;55(3):516-23. doi: 10.1210/jcem-55-3-516.
An assay for plasma free glucocorticoid receptor-binding activity has been developed with the use of specific glucocorticoid receptors in cultured rat pituitary tumor cells (GC line). Unlike other assays for corticosteroids, this assay measures the summed free (rather than the total) receptor-binding activity of all natural and synthetic steroids present in the sample. Plasma samples (0.5 ml) were incubated with [3H]dexamethasone and GC cells at 37 C for 45 min, and the nuclear bound dexamethasone was then measured. The free glucocorticoid receptor-binding activity was determined by the extent to which steroids present in the sample inhibit binding of the 3H-labeled steroids. Free cortisol concentrations of 0.3-3.6 micrograms/dl were accurately detected. That the assay measures free but not total steroids and that the free steroid provides the correct index of receptor-occupying capability were verified by two findings: 1) the assay yields similar results when the free cortisol is separated from plasma and then run in the assay, and 2) the receptor-binding activity of dexamethasone in plasma is reduced to the extent of plasma binding of this steroid measured directly. Free receptor-binding activity of adult plasma taken at various times determined by the assay correlated well with that expected from the total cortisol levels (measured by the corticosteroid-binding globulin-isotope assay) and the extent of plasma binding. The utility of the assay for measuring plasma dexamethasone levels after oral administration of the steroid is shown. The assay should be useful to determine the free glucocorticoid receptor-binding activity in plasma due to cortisol, synthetic glucocorticoids, or unidentified medication. In most circumstances, i.e. when antagonists are not present in sufficient quantities, such activity should equal the free glucocorticoid activity as well.
利用培养的大鼠垂体肿瘤细胞(GC系)中的特异性糖皮质激素受体,开发了一种血浆游离糖皮质激素受体结合活性测定法。与其他皮质类固醇测定法不同,该测定法测量样品中存在的所有天然和合成类固醇的总游离(而非总)受体结合活性。将血浆样品(0.5 ml)与[3H]地塞米松和GC细胞在37℃孵育45分钟,然后测量核结合的地塞米松。游离糖皮质激素受体结合活性通过样品中存在的类固醇抑制3H标记类固醇结合的程度来确定。准确检测到游离皮质醇浓度为0.3 - 3.6微克/分升。该测定法测量游离而非总类固醇,且游离类固醇提供正确的受体占据能力指标这一点通过两个发现得到验证:1)当游离皮质醇从血浆中分离出来然后在测定中运行时,该测定法产生相似的结果;2)血浆中地塞米松的受体结合活性降低到直接测量的该类固醇血浆结合程度。通过该测定法在不同时间测定的成人血浆游离受体结合活性与根据总皮质醇水平(通过皮质类固醇结合球蛋白 - 同位素测定法测量)和血浆结合程度预期的结果密切相关。展示了该测定法在口服类固醇后测量血浆地塞米松水平的效用。该测定法对于确定由于皮质醇、合成糖皮质激素或不明药物导致的血浆中游离糖皮质激素受体结合活性应该是有用的。在大多数情况下,即当拮抗剂不存在足够量时,这种活性也应该等于游离糖皮质激素活性。